JP2023511331A5 - - Google Patents

Info

Publication number
JP2023511331A5
JP2023511331A5 JP2022543677A JP2022543677A JP2023511331A5 JP 2023511331 A5 JP2023511331 A5 JP 2023511331A5 JP 2022543677 A JP2022543677 A JP 2022543677A JP 2022543677 A JP2022543677 A JP 2022543677A JP 2023511331 A5 JP2023511331 A5 JP 2023511331A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
sequence shown
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022543677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511331A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013423 external-priority patent/WO2021146413A1/en
Publication of JP2023511331A publication Critical patent/JP2023511331A/ja
Publication of JP2023511331A5 publication Critical patent/JP2023511331A5/ja
Pending legal-status Critical Current

Links

JP2022543677A 2020-01-16 2021-01-14 骨髄腫細胞および卵巣がん細胞に特異的なヒト化抗体 Pending JP2023511331A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062961768P 2020-01-16 2020-01-16
US62/961,768 2020-01-16
PCT/US2021/013423 WO2021146413A1 (en) 2020-01-16 2021-01-14 Humanized antibodies specific for myeloma and ovarian cancer cells

Publications (2)

Publication Number Publication Date
JP2023511331A JP2023511331A (ja) 2023-03-17
JP2023511331A5 true JP2023511331A5 (https=) 2024-01-22

Family

ID=76864708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022543677A Pending JP2023511331A (ja) 2020-01-16 2021-01-14 骨髄腫細胞および卵巣がん細胞に特異的なヒト化抗体

Country Status (6)

Country Link
US (1) US20230138520A1 (https=)
EP (1) EP4090433A4 (https=)
JP (1) JP2023511331A (https=)
KR (1) KR20220129044A (https=)
CA (1) CA3167936A1 (https=)
WO (1) WO2021146413A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376654B1 (en) * 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US7226750B1 (en) * 2000-08-08 2007-06-05 Molecular Discoveries, Inc. Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2008133857A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
CA2785907A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
WO2016040767A2 (en) * 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
JP6749589B2 (ja) * 2015-07-31 2020-09-02 国立大学法人北海道大学 抗Eva1タンパク質抗体
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
US20220119478A1 (en) * 2019-01-15 2022-04-21 Caerus Therapeutics, Corp. Advanced chimeric antigen receptor vectors for targeting solid tumors

Similar Documents

Publication Publication Date Title
CN112574307B (zh) 抗人Claudin18.2抗体及其应用
CN113264998B (zh) 抗新冠病毒SARS-CoV-2表面S1蛋白的单链抗体及其应用
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
RU2430112C2 (ru) Композиции и способы диагностики и лечения опухоли
CN113150129B (zh) 抗新冠病毒SARS-CoV-2表面S2蛋白的单链抗体及其应用
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2020522261A5 (https=)
JP2013506428A5 (https=)
CN113874399A (zh) 抗ror1/抗cd3双特异性结合分子
JP2018511319A5 (https=)
CN112552401A (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN113683697B (zh) 抗b7-h3抗体、其制备方法及用途
JP2021530244A5 (https=)
CN112538112A (zh) 抗α-溶血素的抗体及其应用
JP2024502091A5 (https=)
EP3694879A1 (en) Antibodies targeting pdl1 and methods of use thereof
CN109721656B (zh) 靶向rankl的治疗性抗体
JP2023518225A5 (https=)
JP2025505650A5 (https=)
CN119285774A (zh) 抗人tigit单克隆抗体tigit-m007或其功能性片段及其应用
EP2778173A1 (en) Antibody directed against anthrax toxins and its uses
JP2023511331A5 (https=)
WO2025213712A1 (zh) 基于ai从头设计筛选合成的her2蛋白特异性结合抗体及其应用
CN114213539B (zh) 可结合cd4的纳米抗体4nb357及其应用
CN112805297A (zh) 抗人类pd-l1抗体及其用途